Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details)

v3.22.2.2
Summary of Significant Accounting Policies (Details)
$ in Thousands
 12 Months Ended
Jul. 31, 2022
USD ($)
shares
Jul. 31, 2021
USD ($)
shares
Jul. 31, 2020
USD ($)
shares
Summary of Significant Accounting Policies (Details) [Line Items]      
Number of operating segments 3    
Accumulated deficit $ 288,261    
Net loss (18,261) $ 7,875 $ (28,520)
Net Cash Provided by (Used in) Operating Activities (16,590) 387 $ (17,179)
Fair value of investments   29,978  
Fair value investments cost basis   30,061  
Unrealized Loss on Securities   $ 83  
Realized loss $ 1,283    
Contractual adjustment percentages 83.00% 83.00% 88.00%
Receivables     $ 6,180
Income before taxes $ 839    
Carrying amount 55,000    
Advertising expense $ 577 $ 400 437
Weighted average stock options (in Shares) | shares   134,000  
Weighted average shares outstanding (in Shares) | shares 472,000    
Share-based compensation expense $ 1,496 $ 907 933
Employee benefits and share based compensation     10
Common Stock [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Net loss
Weighted average shares outstanding (in Shares) | shares     40,000
Clinical Revenue [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Concentration risk percentage 44.00% 48.00% 8.00%
Clinical Labs [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Receivable percentage 59.00%    
Receivables     $ 9,141
Accounts receivables percentage     68.00%
Life Science Receivables [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Receivables     $ 2,961
Accounts receivables percentage     32.00%
Minimum [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Finite-lived intangible asset, useful life 4 years    
Maximum [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Finite-lived intangible asset, useful life 15 years    
Patents [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Finite-lived intangible asset, useful life 10 years    
Out of the Money [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Weighted average shares outstanding (in Shares) | shares 1,499,000 1,465,000 1,904,000
Foreign Bank [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Cash and cash equivalents $ 590 $ 909  
Building and Building Improvements [Member] | Minimum [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Property, plant and equipment, useful life 15 years    
Building and Building Improvements [Member] | Maximum [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Property, plant and equipment, useful life 30 years    
Machinery and Equipment [Member] | Minimum [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Property, plant and equipment, useful life 3 years    
Machinery and Equipment [Member] | Maximum [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Property, plant and equipment, useful life 10 years    
Third Party Payer [Member] | Revenue Benchmark [Member] | Clinical Revenue [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Clinical Services net revenue 21.00% 22.00% 24.00%
Clinical Services net accounts receivable percentage 23.00% 27.00%  
Health Maintenance Organization [Member] | Revenue Benchmark [Member] | Clinical Revenue [Member]      
Summary of Significant Accounting Policies (Details) [Line Items]      
Clinical Services net revenue 11.00% 13.00%